The chlorite-based drug WF10 constantly reduces hemoglobin A1c values and improves glucose control in diabetes patients with severe foot syndrome

•The chlorite-based drug WF10 improved healing of foot wounds in diabetic patients.•Infusion with WF10 markedly reduced HbA1c values in patients with diabetic foot syndrome.•After administration of WF10 HbA1c values remained low over at least 8 to 12 weeks.•The chlorite component of WF10 is known to inactivate efficiently cytotoxic hemoglobin forms.•This treatment prevented below knee amputation in patients with diabetic foot syndrome.

AimsThe intravenous application of the chlorite-based drug solution WF10 is known to improve wound healing in patients with diabetic foot syndrome. In this retrospective study, we addressed the question, which effects are caused by this drug in patients with diabetic foot ulcers on the hemoglobin A1c value.MethodsPatients received five consecutive daily infusions of WF10. Three patients received a second cycle of WF10, and one patient a third cycle.ResultsOn a group of twelve patients with diabetic foot syndrome, WF10 gradually reduced the HbA1c values from a high-risk range (9.1 ± 1.6% (76 ± 13 mmol/mol)) into a low-risk range in all patients but one. These values remain low over at least 8 to 12 weeks after the administration of WF10. This drug improved also considerably wound healing processes in eleven patients.ConclusionsThe chlorite component of WF10 is known to inactivate efficiently free cytotoxic hemoglobin forms that might accumulate in peripheral blood after hemolysis and induces the removal of pre-damaged red blood cells from circulation. By these mechanisms WF10 diminished toxic effects of hemolysis, improved microcirculation and glucose consumption in affected tissues, and prevented, thus, below knee amputation.

Graphical AbstractFigure optionsDownload full-size imageDownload as PowerPoint slide